Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids.
Vaissière T., Cuenin C., Paliwal A., Vineis P., Hoek G., Krzyzanowski M., Airoldi L., Dunning A., Garte S., Hainaut P., Malaveille C., Overvad K., Clavel-Chapelon F., Linseisen J., Boeing H., Trichopoulou A., Trichopoulos D., Kaladidi A., Palli D., Krogh V., Tumino R., Panico S., Bueno-De-Mesquita HB., Peeters PH., Kumle M., Gonzalez CA., Martinez C., Dorronsoro M., Barricarte A., Navarro C., Quiros JR., Berglund G., Janzon L., Jarvholm B., Day NE., Key TJ., Saracci R., Kaaks R., Riboli E., Hainaut P., Herceg Z.
Cell-free circulating DNA isolated from the plasma of individuals with cancer has been shown to harbor cancer-associated changes in DNA methylation, and thus it represents an attractive target for biomarker discovery. However, the reliable detection of DNA methylation changes in body fluids has proven to be technically challenging. Here we describe a novel combination of methods that allows quantitative and sensitive detection of DNA methylation in minute amounts of DNA present in body fluids (quantitative Methylation Analysis of Minute DNA amounts after whole Bisulfitome Amplification, qMAMBA). This method involves genome-wide amplification of bisulphite-modified DNA template followed by quantitative methylation detection using pyrosequencing and allows analysis of multiple genes from a small amount of starting DNA. To validate our method we used qMAMBA assays for four genes and LINE1 repetitive sequences combined with plasma DNA samples as a model system. qMAMBA offered high efficacy in the analysis of methylation levels and patterns in plasma samples with extremely small amounts of DNA and low concentrations of methylated alleles. Therefore, qMAMBA will facilitate methylation studies aiming to discover epigenetic biomarkers, and should prove particularly valuable in profiling a large sample series of body fluids from molecular epidemiology studies as well as in tracking disease in early diagnostics.